Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
20 07 2020
20 07 2020
Historique:
pubmed:
29
5
2020
medline:
27
2
2021
entrez:
29
5
2020
Statut:
ppublish
Résumé
NCI-MATCH is a nationwide, histology-agnostic, signal-finding, molecular profile-driven trial for patients with refractory cancers, lymphomas, or myelomas. Patients with tumors harboring actionable aberration(s) in fibroblast growth factor receptor ( Patients' tumors were screened by next-generation sequencing for predefined Between July 2016 and June 2017, 70 patients were assigned and 48 received protocol therapy and are eligible for analysis. Patients' tumors harbored Preliminary signals of activity appeared to be limited to cancers harboring
Identifiants
pubmed: 32463741
doi: 10.1200/JCO.19.02630
pmc: PMC7367548
doi:
Substances chimiques
AZD4547
0
Benzamides
0
Piperazines
0
Pyrazoles
0
Banques de données
ClinicalTrials.gov
['NCT02465060']
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2407-2417Subventions
Organisme : NCI NIH HHS
ID : U10 CA180858
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233302
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180828
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180855
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180820
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180794
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233328
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180790
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233180
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180870
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180867
Pays : United States
Déclaration de conflit d'intérêts
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.
Références
J Clin Oncol. 2018 Jan 20;36(3):276-282
pubmed: 29182496
Mol Cancer Ther. 2017 Apr;16(4):637-648
pubmed: 28119489
N Engl J Med. 2019 Jul 25;381(4):338-348
pubmed: 31340094
Lancet Oncol. 2015 Jun;16(6):686-94
pubmed: 25981814
Nature. 2014 Mar 20;507(7492):315-22
pubmed: 24476821
J Mol Biol. 2014 Nov 11;426(22):3744-3756
pubmed: 25219510
Cancer Discov. 2013 Jun;3(6):636-47
pubmed: 23558953
J Mol Diagn. 2017 Mar;19(2):313-327
pubmed: 28188106
Clin Cancer Res. 2017 Oct 15;23(20):6138-6150
pubmed: 28751448
Clin Cancer Res. 2012 Dec 15;18(24):6658-67
pubmed: 23082000
Nat Rev Cancer. 2010 Feb;10(2):116-29
pubmed: 20094046
Clin Cancer Res. 2013 May 1;19(9):2572-83
pubmed: 23493349
Cancer Discov. 2018 Jul;8(7):812-821
pubmed: 29848605
Nat Rev Clin Oncol. 2015 Oct;12(10):573-83
pubmed: 26122181
Ann Oncol. 2017 Jun 1;28(6):1316-1324
pubmed: 29177434
Science. 2012 Sep 7;337(6099):1231-5
pubmed: 22837387
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Invest New Drugs. 2017 Aug;35(4):451-462
pubmed: 28070720
J Bone Miner Res. 2011 Oct;26(10):2486-97
pubmed: 21812026
J Biochem. 2011 Feb;149(2):121-30
pubmed: 20940169
Clin Cancer Res. 2006 Nov 15;12(22):6652-62
pubmed: 17121884
Nat Rev Cancer. 2017 May;17(5):318-332
pubmed: 28303906
Am J Clin Pathol. 2016 Jan;145(1):55-61
pubmed: 26712871
J Clin Oncol. 2017 Jan 10;35(2):157-165
pubmed: 27870574
J Thorac Oncol. 2019 Oct;14(10):1847-1852
pubmed: 31195180
Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8713-7
pubmed: 18552176
EMBO Mol Med. 2011 Mar;3(3):167-80
pubmed: 21337521
Clin Cancer Res. 2019 Aug 15;25(16):4888-4897
pubmed: 31088831
Cancer Discov. 2013 Mar;3(3):264-79
pubmed: 23418312
Clin Cancer Res. 2017 Sep 15;23(18):5366-5373
pubmed: 28615371
Nat Genet. 2013 Dec;45(12):1446-51
pubmed: 24185510
Clin Cancer Res. 2015 Jun 15;21(12):2684-94
pubmed: 26078430
Nat Genet. 2013 Dec;45(12):1439-45
pubmed: 24185512
Cancer Med. 2013 Aug;2(4):437-46
pubmed: 24156016
Gut. 2012 May;61(5):673-84
pubmed: 22315472
Cancer Discov. 2016 Aug;6(8):838-851
pubmed: 27179038
Clin Cancer Res. 2014 Aug 1;20(15):4107-14
pubmed: 24850843
Oncotarget. 2017 Feb 28;8(9):16052-16074
pubmed: 28030802
Sci Transl Med. 2010 Dec 15;2(62):62ra93
pubmed: 21160078
Clin Cancer Res. 2017 Aug 1;23(15):4323-4334
pubmed: 28381415
Cancer Res. 2012 Apr 15;72(8):2045-56
pubmed: 22369928
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Clin Cancer Res. 2020 Feb 15;26(4):764-774
pubmed: 31585937